Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
William L BakerJan Beyer-WestendorfThomas J BunzDaniel ErikssonAnna-Katharina MeineckeNitesh A SoodCraig I ColemanPublished in: Diabetes, obesity & metabolism (2019)
Among patients with NVAF and T2D treated in routine practice, rivaroxaban was associated with lower risks of both MACE and MALE versus warfarin, with no significant difference in major bleeding.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- type diabetes
- direct oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- heart failure
- healthcare
- primary care
- percutaneous coronary intervention
- venous thromboembolism
- clinical practice
- glycemic control
- human health
- insulin resistance
- risk assessment
- adverse drug
- metabolic syndrome
- emergency department
- adipose tissue
- quality improvement
- left ventricular
- mitral valve